B-Cell Maturation Antigen (BCMA), a Target for Multiple Myeloma

BCMA is selectively induced during plasma cell differentiation and is nearly absent on naive and memory B cells^[1,2]. The interaction between BCMA and its ligand BAFF and APRIL is involved for the maintenance of long-lived plasma cells ^[3,4]. BCMA is an ideal target for cancers of plasma cells, because it’s not expressed in other major organs. Dozens of BCMA-targeting therapies, including chimeric antigen receptor T (CAR-T) cells, antibody-drug conjugate, and Bi-specific antibodies, are currently being developed and tested clinically. Leading the pack is Bluebird and Celgene’s bb2121. A phase I multi-center clinical trial has demonstrated a stunning 80% response rate in multiple myeloma patients. These approaches, if successfully established, will bring multiple myeloma patients a much needed option beyond Daratumumab (anti-CD38 antibody) and Elotuzumab (anti-SLAMF7).

The interactions between BAFF / APRIL and their receptors are selective. Note BCMA can interact with both BAFF and APRIL^[5]. The affinity of APRIL-BCMA interaction, however, is much higher than that of BAFF-BCMA binding^[6].

ACROBiosystems provides a comprehensive panel of BCMA proteins, including the exclusive biotinylated BCMA (Cat. No. BC7-H82F0) and the monomeric BCMA (Cat. No. BCA-H522y). We also offer BCMA related proteins, such as BAFF and BAFFR proteins.

Product Validation Data

293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-labeled human BCMA / TNFRSF17 protein, Fc tag (Cat. No. BCA-HF254, 3 μg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled human BCMA / TNFRSF17 protein, Fc tag (Cat. No. BCA-HF254).

Protocol

Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1e6 cells were first incubated with 50ul Biotinylated Human BCMA, Fc,Avitag (Cat. No. BC7-H82F0, 8 μg/ml ), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma).

Protocol

We offer a variety of ready-to-use biotinylated proteins using our in-house developed labeling techniques, which confer high bioactivity and minimal batch-to-batch variation. In addition, we also offer FITC-labeled BCMA and BAFF proteins.

BCMA Product List

Molecule	Cat. No.	Species	Structure	Purity	Features
BCMA (Biotin-labeled)	BC7-H82F0
BCMA (FITC-Labeled)	BCA-HF254
BCMA	BCA-H522y
BCMA	BC7-H5254
BCMA (Biotin-labeled)	BCA-M82F0
BCMA (Biotin-labeled)	BCA-M5258
BCMA (Biotin-labeled)	BCA-C82F4
BCMA	BCA-C5253

Other Relevant Products

Molecule	Cat. No.	Species	Structure	Purity	Features
BAFF (Biotin-labeled)	BAF-H82F3
BAFF (Biotin-labeled)	BAF-H82Q2
BAFF	BAF-M5257
BAFFR (Biotin-labeled)	BAR-M82F0
BAFFR	BAR-M5259
BAFFR	BAR-H5257
APRIL (Biotin-labeled)	APL-H82F5

Other Multiple Myeloma Targets

Molecule	Cat. No.	Species	Structure	Purity	Features
CD38 (Biotin-labeled)	CD8-H82E7
CD38	CD8-H5224
SLAMF7 (Biotin-labeled)	SL7-H82E0
SLAMF7	SL7-H5225
SLAMF7	SL7-H5256

Customer Reviews

Related Articles

• PD-1 Pathway Recombinant Protein Collection

• Biotinylated CD3E & more CD3 products

• Targets of CAR-T Cell Therapy

• TIGIT Signaling Axis

• Leukocyte Surface Antigen CD47

• Lymphocyte-activation gene 3 (LAG-3)

• Recombinant ROR1 & ROR2 Proteins

References

• Avery et al., 2004, J Clin Invest. 112, 286–297.

• Chiu et al., 2007, Blood 109, 729–739.

• O'Connor et al., 2004, J. Exp. Med. 199, 91–98.

• Peperzak et al., 2013, Nat. Immunol. 14, 290–297.

• Bolkun et al., 2016, J. Cancer 7, 1979–1983.

• Bossen and Schneider, 2006, Semin. Immunol. 18, 263–275.